RECURRENT CORNEAL MELTING IN A PATIENT WITH STAGE IV LUNG ADENOCARCINOMA: A CASE REPORT
Published 2022 - 26th ESCRS Winter Meeting
Reference: P137 | Type: Abstracts | DOI: 10.82333/a4fk-b157
Authors: Nuria Cuenca Cardeñosa* 1 , Maria Luisa Perez Gancedo 1 , Maria Platero Vazquez 1 , Maria Mercedes Cabezas Leon 1 , Maria Angeles Leal Gonzalez 1 , Laura Alonso Martin 1 , Alfonso Rubio Reina 1
1Ophthalmology,Toledo Hospital Complex,Madrid,Spain
Purpose
To show the management of a patient with stage IV lung adenocarcinoma under chemotherapy treatment with Bevacizumab, Carboplatin and Paclitaxel, who presents recurrent and spontaneous corneal melting.
Setting
69-year-old male patient diagnosed in 2019 with stage IV lung adenocarcinoma under current treatment with Bevazicumab, Carboplatin and Paclitaxel. He went to the emergency room due to a red left eye with pain, with a diagnosis of spontaneous central corneal perforation. It was decided to place Hystoacril and contact lens. In subsequent check-ups, a thinned corneal ulcer was observed in the right eye with a thickness greater than 50%, so it was decided to place Hystoacril and contact lens also. Surgery was scheduled to place amniotic membrane in both eyes, but due to a low platelet count, the intervention could not be performed. A new thinned ulcer was discovered in the right eye not previously described, so Hystoacril was placed again on the ulcer, in the operating room. The patient is currently with Hystoacril and contact lens in both eyes, undergoing topical antibiotic treatment, artificial tears, and oral doxycycline, waiting to finish chemotherapy and an analysis to reevaluate platelets.
Methods
69-year-old patient with stage IV lung adenocarcinoma undergoing chemotherapeutic treatment at Toledo Hospital Complex (Spain), with recurrent and spontaneous corneal melting.
Results
Spontaneous ocular perforation and recurrent corneal melting in a patient undergoing chemotherapeutic treatment with Bevazicumab, Carboplatin and Paclitaxel, treated with Hystoacril and contact lens. When he has an adequate analysis, an amniotic membrane will be placed in both eyes in the operating room.
Conclusion
Corneal melting in this patient may be due to the toxicity of chemotherapy treatment. In the literature, ocular surface toxicity in cancer patients is more related to EGFR inhibitors and Pembrolizumab. Therefore, we must pay attention to the ocular surface of cancer patients regardless of the chemotherapy treatment they are with.